PATENT CLAIM ANALYSIS

Application Number: 15878295
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["514", "019300"]

Abstract:
Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.

Claim (Index 12):
The nanoparticle of  claim 11 , wherein the targeting agent is configured to bind to a VLA-4 receptor of a target cell, the therapeutic agent comprises doxorubicin, and the pH-sensitive bond is configured to hydrolyze at the pH of an endocytic vesicle of the target cell.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 86.0
- Lexical Diversity: 1.80328
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14356121', '15413267', '14765620', '15301020', '12573591']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7203036552476246
- 35 USC 102 Novelty (BERT): 0.5493881098447491
- Combined Prediction Score: 0.7032121007073371
- Mean Citation Score: 256.094844
- Max Citation Score: 401.60403
- Similarity Product: 341.23900812906504

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test